Amy L. Walters

VP, Clinical and Regulatory Affairs

Amy joined Sequent in March 2011, and has served as an advisor to the Company since 2010. From 2008 to 2011, she ran a successful consulting business that provided regulatory, clinical and quality assistance to several cardiovascular, neurovascular, ophthalmology, and orthopedics companies. From 2002 to 2007, Amy served as Vice President, Clinical and Regulatory Affairs and Quality Assurance for the Neurovascular Division of ev3, formerly MicroTherapeutics, Inc. During her tenure, Amy played a key role in the development of the global neurovascular franchise, and led the Company through a successful PMA submission, FDA Advisory Panel, and ultimate US regulatory approval for the liquid embolic, Onyx. From 1999 to 2002, she was Director, Clinical and Regulatory at Biosense Webster, a Johnson & Johnson Company. Prior to J&J, she held various clinical, regulatory, and quality positions at Smith & Nephew, Johnson & Johnson, and Summit Technology. Amy earned Bachelor of Arts degrees in both History and Science at Harvard University.